Form 8-K - Current report:
SEC Accession No. 0001193125-25-290638
Filing Date
2025-11-21
Accepted
2025-11-21 08:03:29
Documents
13
Period of Report
2025-11-21
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d65279d8k.htm   iXBRL 8-K 37224
  Complete submission text file 0001193125-25-290638.txt   200451

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA xoma-20251121.xsd EX-101.SCH 4581
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE xoma-20251121_def.xml EX-101.DEF 14450
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE xoma-20251121_lab.xml EX-101.LAB 24600
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xoma-20251121_pre.xml EX-101.PRE 15483
16 EXTRACTED XBRL INSTANCE DOCUMENT d65279d8k_htm.xml XML 7796
Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Royalty Corp (Filer) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39801 | Film No.: 251504650
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)